Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|December 1, 2011
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-12-01-2011
- Volume 23
- Issue 12
Contract API Manufacturing: The Year in Review
Expansion activity was limited as fine-chemical producers and CMOs of API and intermediates grapple with changing industry fundamentals.
Advertisement
By Patricia van Arnum
The year 2011 was another year of transition for fine-chemical producers and contract manufacturers of APIs and intermediates. As the pharmaceutical industry as a whole deals with slowing growth, increased generic-drug incursion, reduced R&D productivity, and the financing pinch for smaller and emerging bio/pharmaceutical companies, so do its suppliers. Expansion activity among fine-chemical producers and contract API manufacturers was limited although certain areas, such as high-potency manufacturing, continue to attract investment as do biopharmaceutical manufacturing and related services.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
almost 15 years ago
Mitigating Personnel Risksalmost 15 years ago
The Impact Of Single-Use Systemsalmost 15 years ago
Contamination: Invisible And Airbornealmost 15 years ago
Avoiding Contamination Risks in Aseptic Processesalmost 15 years ago
Choosing Cleanroom Clothingalmost 15 years ago
The Employment Outlook Brightensalmost 15 years ago
It’s déjà vu all over againalmost 15 years ago
Newsalmost 15 years ago
The Development of a Floating Drug-Delivery System for Metronidazolealmost 15 years ago
Impact of AgeingAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
5